Global Juvenile Diabetes Market
Global Juvenile Diabetes Market

Juvenile Diabetes Comprehensive Study by Type (Drugs, Delivery Devices), Application (Hospitals, Clinics, Medical Centers), Insulin Analog Type (Rapid-Acting Insulin Analogs, Long-Acting Insulin Analogs, Premix Insulin Analogs) Players and Region - Global Market Outlook to 2024

Juvenile Diabetes Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024 | CAGR: 6.17%  

May 2019 Edition 250 Pages 198 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Key Players:
Eli Lilly and Company (United States), Bayer Pharmaceuticals (Germany), Sanofi (France), Novo Nordisk (Denmark), AstraZeneca PLC. (United Kingdom), XOMA Corp (United States), DiaVacs Inc. (United States), B.BraunMelsungen AG (Germany), Biodel Inc. (United States), Macrogenics Inc. (United States), Takeda Pharmaceutical (Japan) and Wockhardt Ltd. (India)

In the last few years, Global market of Juvenile Diabetes developed rapidly, with an average growth rate of 6.17% . Major factors driving the market are Increasing Rate of Advances in Insulin Delivery Devices .

On the basis of product type, the Juvenile Diabetes market is segmented by Drugs and Delivery Devices.

On the basis of applications, the Juvenile Diabetes market is segmented by Hospitals, Clinics and Medical Centers.

The Players having strong hold in the market are Novo Nordisk (Denmark), AstraZeneca PLC. (United Kingdom), Sanofi (France). . The Global Juvenile Diabetes market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Juvenile Diabetes market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Juvenile Diabetes market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Original Equipment Manufacturers (OEMs), Healthcare Service Providers, Research Laboratories and Academic Institutes, Product Sales and Distribution Companies, Pharmaceutical and Biotechnology Companies, Clinical Research Organizations (CROs), Research and Development Companies and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Drugs
  • Delivery Devices
By Application
  • Hospitals
  • Clinics
  • Medical Centers
By Insulin Analog Type
  • Rapid-Acting Insulin Analogs
  • Long-Acting Insulin Analogs
  • Premix Insulin Analogs

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Rate of Advances in Insulin Delivery Devices
      • 3.2.2. Growth in the Number of Juvenile Diabetic Patients in Developed Economies
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Requirements for Product Approval
      • 3.3.2. High Product Manufacturing Costs
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in HI Delivery Devices
      • 3.4.2. Increasing Demand for Artificial Pancreas and Home Infusion Therapy for Diabetes Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Juvenile Diabetes, by Type, Application, Insulin Analog Type and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Juvenile Diabetes (Value)
      • 5.2.1. Global Juvenile Diabetes by: Type (Value)
        • 5.2.1.1. Drugs
        • 5.2.1.2. Delivery Devices
      • 5.2.2. Global Juvenile Diabetes by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Medical Centers
      • 5.2.3. Global Juvenile Diabetes by: Insulin Analog Type (Value)
        • 5.2.3.1. Rapid-Acting Insulin Analogs
        • 5.2.3.2. Long-Acting Insulin Analogs
        • 5.2.3.3. Premix Insulin Analogs
      • 5.2.4. Global Juvenile Diabetes Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Juvenile Diabetes (Volume)
      • 5.3.1. Global Juvenile Diabetes by: Type (Volume)
        • 5.3.1.1. Drugs
        • 5.3.1.2. Delivery Devices
      • 5.3.2. Global Juvenile Diabetes by: Application (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Clinics
        • 5.3.2.3. Medical Centers
      • 5.3.3. Global Juvenile Diabetes by: Insulin Analog Type (Volume)
        • 5.3.3.1. Rapid-Acting Insulin Analogs
        • 5.3.3.2. Long-Acting Insulin Analogs
        • 5.3.3.3. Premix Insulin Analogs
      • 5.3.4. Global Juvenile Diabetes Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Juvenile Diabetes (Price)
      • 5.4.1. Global Juvenile Diabetes by: Type (Price)
  • 6. Juvenile Diabetes: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eli Lilly and Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer Pharmaceuticals (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novo Nordisk (Denmark)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca PLC. (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. XOMA Corp (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. DiaVacs Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. B.BraunMelsungen AG (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Biodel Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Macrogenics Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Takeda Pharmaceutical (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Wockhardt Ltd. (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Juvenile Diabetes Sale, by Type, Application, Insulin Analog Type and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Juvenile Diabetes (Value)
      • 7.2.1. Global Juvenile Diabetes by: Type (Value)
        • 7.2.1.1. Drugs
        • 7.2.1.2. Delivery Devices
      • 7.2.2. Global Juvenile Diabetes by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Medical Centers
      • 7.2.3. Global Juvenile Diabetes by: Insulin Analog Type (Value)
        • 7.2.3.1. Rapid-Acting Insulin Analogs
        • 7.2.3.2. Long-Acting Insulin Analogs
        • 7.2.3.3. Premix Insulin Analogs
      • 7.2.4. Global Juvenile Diabetes Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Juvenile Diabetes (Volume)
      • 7.3.1. Global Juvenile Diabetes by: Type (Volume)
        • 7.3.1.1. Drugs
        • 7.3.1.2. Delivery Devices
      • 7.3.2. Global Juvenile Diabetes by: Application (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Clinics
        • 7.3.2.3. Medical Centers
      • 7.3.3. Global Juvenile Diabetes by: Insulin Analog Type (Volume)
        • 7.3.3.1. Rapid-Acting Insulin Analogs
        • 7.3.3.2. Long-Acting Insulin Analogs
        • 7.3.3.3. Premix Insulin Analogs
      • 7.3.4. Global Juvenile Diabetes Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Juvenile Diabetes (Price)
      • 7.4.1. Global Juvenile Diabetes by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Juvenile Diabetes: by Type(USD Million)
  • Table 2. Juvenile Diabetes Drugs , by Region USD Million (2013-2018)
  • Table 3. Juvenile Diabetes Delivery Devices , by Region USD Million (2013-2018)
  • Table 4. Juvenile Diabetes: by Application(USD Million)
  • Table 5. Juvenile Diabetes Hospitals , by Region USD Million (2013-2018)
  • Table 6. Juvenile Diabetes Clinics , by Region USD Million (2013-2018)
  • Table 7. Juvenile Diabetes Medical Centers , by Region USD Million (2013-2018)
  • Table 8. Juvenile Diabetes: by Insulin Analog Type(USD Million)
  • Table 9. Juvenile Diabetes Rapid-Acting Insulin Analogs , by Region USD Million (2013-2018)
  • Table 10. Juvenile Diabetes Long-Acting Insulin Analogs , by Region USD Million (2013-2018)
  • Table 11. Juvenile Diabetes Premix Insulin Analogs , by Region USD Million (2013-2018)
  • Table 12. South America Juvenile Diabetes, by Country USD Million (2013-2018)
  • Table 13. South America Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 14. South America Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 15. South America Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 16. Brazil Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 17. Brazil Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 18. Brazil Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 19. Argentina Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 20. Argentina Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 21. Argentina Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 22. Rest of South America Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 23. Rest of South America Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 24. Rest of South America Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 25. Asia Pacific Juvenile Diabetes, by Country USD Million (2013-2018)
  • Table 26. Asia Pacific Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 27. Asia Pacific Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 28. Asia Pacific Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 29. China Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 30. China Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 31. China Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 32. Japan Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 33. Japan Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 34. Japan Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 35. India Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 36. India Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 37. India Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 38. South Korea Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 39. South Korea Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 40. South Korea Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 41. Taiwan Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 42. Taiwan Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 43. Taiwan Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 44. Australia Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 45. Australia Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 46. Australia Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 47. Rest of Asia-Pacific Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 48. Rest of Asia-Pacific Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 49. Rest of Asia-Pacific Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 50. Europe Juvenile Diabetes, by Country USD Million (2013-2018)
  • Table 51. Europe Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 52. Europe Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 53. Europe Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 54. Germany Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 55. Germany Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 56. Germany Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 57. France Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 58. France Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 59. France Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 60. Italy Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 61. Italy Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 62. Italy Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 63. United Kingdom Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 64. United Kingdom Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 65. United Kingdom Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 66. Netherlands Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 67. Netherlands Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 68. Netherlands Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 69. Rest of Europe Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 70. Rest of Europe Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 71. Rest of Europe Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 72. MEA Juvenile Diabetes, by Country USD Million (2013-2018)
  • Table 73. MEA Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 74. MEA Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 75. MEA Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 76. Middle East Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 77. Middle East Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 78. Middle East Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 79. Africa Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 80. Africa Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 81. Africa Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 82. North America Juvenile Diabetes, by Country USD Million (2013-2018)
  • Table 83. North America Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 84. North America Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 85. North America Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 86. United States Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 87. United States Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 88. United States Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 89. Canada Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 90. Canada Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 91. Canada Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 92. Mexico Juvenile Diabetes, by Type USD Million (2013-2018)
  • Table 93. Mexico Juvenile Diabetes, by Application USD Million (2013-2018)
  • Table 94. Mexico Juvenile Diabetes, by Insulin Analog Type USD Million (2013-2018)
  • Table 95. Juvenile Diabetes Sales: by Type(Units)
  • Table 96. Juvenile Diabetes Sales Drugs , by Region Units (2013-2018)
  • Table 97. Juvenile Diabetes Sales Delivery Devices , by Region Units (2013-2018)
  • Table 98. Juvenile Diabetes Sales: by Application(Units)
  • Table 99. Juvenile Diabetes Sales Hospitals , by Region Units (2013-2018)
  • Table 100. Juvenile Diabetes Sales Clinics , by Region Units (2013-2018)
  • Table 101. Juvenile Diabetes Sales Medical Centers , by Region Units (2013-2018)
  • Table 102. Juvenile Diabetes Sales: by Insulin Analog Type(Units)
  • Table 103. Juvenile Diabetes Sales Rapid-Acting Insulin Analogs , by Region Units (2013-2018)
  • Table 104. Juvenile Diabetes Sales Long-Acting Insulin Analogs , by Region Units (2013-2018)
  • Table 105. Juvenile Diabetes Sales Premix Insulin Analogs , by Region Units (2013-2018)
  • Table 106. South America Juvenile Diabetes Sales, by Country Units (2013-2018)
  • Table 107. South America Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 108. South America Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 109. South America Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 110. Brazil Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 111. Brazil Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 112. Brazil Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 113. Argentina Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 114. Argentina Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 115. Argentina Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 116. Rest of South America Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 117. Rest of South America Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 118. Rest of South America Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 119. Asia Pacific Juvenile Diabetes Sales, by Country Units (2013-2018)
  • Table 120. Asia Pacific Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 121. Asia Pacific Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 122. Asia Pacific Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 123. China Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 124. China Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 125. China Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 126. Japan Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 127. Japan Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 128. Japan Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 129. India Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 130. India Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 131. India Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 132. South Korea Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 133. South Korea Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 134. South Korea Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 135. Taiwan Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 136. Taiwan Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 137. Taiwan Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 138. Australia Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 139. Australia Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 140. Australia Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 141. Rest of Asia-Pacific Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 142. Rest of Asia-Pacific Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 143. Rest of Asia-Pacific Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 144. Europe Juvenile Diabetes Sales, by Country Units (2013-2018)
  • Table 145. Europe Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 146. Europe Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 147. Europe Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 148. Germany Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 149. Germany Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 150. Germany Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 151. France Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 152. France Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 153. France Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 154. Italy Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 155. Italy Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 156. Italy Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 157. United Kingdom Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 158. United Kingdom Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 159. United Kingdom Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 160. Netherlands Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 161. Netherlands Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 162. Netherlands Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 163. Rest of Europe Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 164. Rest of Europe Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 165. Rest of Europe Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 166. MEA Juvenile Diabetes Sales, by Country Units (2013-2018)
  • Table 167. MEA Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 168. MEA Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 169. MEA Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 170. Middle East Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 171. Middle East Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 172. Middle East Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 173. Africa Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 174. Africa Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 175. Africa Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 176. North America Juvenile Diabetes Sales, by Country Units (2013-2018)
  • Table 177. North America Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 178. North America Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 179. North America Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 180. United States Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 181. United States Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 182. United States Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 183. Canada Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 184. Canada Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 185. Canada Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 186. Mexico Juvenile Diabetes Sales, by Type Units (2013-2018)
  • Table 187. Mexico Juvenile Diabetes Sales, by Application Units (2013-2018)
  • Table 188. Mexico Juvenile Diabetes Sales, by Insulin Analog Type Units (2013-2018)
  • Table 189. Juvenile Diabetes: by Type(USD/Units)
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Juvenile Diabetes: by Type(USD Million)
  • Table 203. Juvenile Diabetes Drugs , by Region USD Million (2019-2024)
  • Table 204. Juvenile Diabetes Delivery Devices , by Region USD Million (2019-2024)
  • Table 205. Juvenile Diabetes: by Application(USD Million)
  • Table 206. Juvenile Diabetes Hospitals , by Region USD Million (2019-2024)
  • Table 207. Juvenile Diabetes Clinics , by Region USD Million (2019-2024)
  • Table 208. Juvenile Diabetes Medical Centers , by Region USD Million (2019-2024)
  • Table 209. Juvenile Diabetes: by Insulin Analog Type(USD Million)
  • Table 210. Juvenile Diabetes Rapid-Acting Insulin Analogs , by Region USD Million (2019-2024)
  • Table 211. Juvenile Diabetes Long-Acting Insulin Analogs , by Region USD Million (2019-2024)
  • Table 212. Juvenile Diabetes Premix Insulin Analogs , by Region USD Million (2019-2024)
  • Table 213. South America Juvenile Diabetes, by Country USD Million (2019-2024)
  • Table 214. South America Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 215. South America Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 216. South America Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 217. Brazil Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 218. Brazil Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 219. Brazil Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 220. Argentina Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 221. Argentina Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 222. Argentina Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 223. Rest of South America Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 224. Rest of South America Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 225. Rest of South America Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 226. Asia Pacific Juvenile Diabetes, by Country USD Million (2019-2024)
  • Table 227. Asia Pacific Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 228. Asia Pacific Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 229. Asia Pacific Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 230. China Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 231. China Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 232. China Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 233. Japan Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 234. Japan Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 235. Japan Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 236. India Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 237. India Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 238. India Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 239. South Korea Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 240. South Korea Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 241. South Korea Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 242. Taiwan Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 243. Taiwan Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 244. Taiwan Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 245. Australia Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 246. Australia Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 247. Australia Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 248. Rest of Asia-Pacific Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 249. Rest of Asia-Pacific Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 250. Rest of Asia-Pacific Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 251. Europe Juvenile Diabetes, by Country USD Million (2019-2024)
  • Table 252. Europe Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 253. Europe Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 254. Europe Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 255. Germany Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 256. Germany Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 257. Germany Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 258. France Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 259. France Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 260. France Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 261. Italy Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 262. Italy Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 263. Italy Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 264. United Kingdom Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 265. United Kingdom Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 266. United Kingdom Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 267. Netherlands Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 268. Netherlands Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 269. Netherlands Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 270. Rest of Europe Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 271. Rest of Europe Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 272. Rest of Europe Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 273. MEA Juvenile Diabetes, by Country USD Million (2019-2024)
  • Table 274. MEA Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 275. MEA Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 276. MEA Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 277. Middle East Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 278. Middle East Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 279. Middle East Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 280. Africa Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 281. Africa Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 282. Africa Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 283. North America Juvenile Diabetes, by Country USD Million (2019-2024)
  • Table 284. North America Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 285. North America Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 286. North America Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 287. United States Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 288. United States Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 289. United States Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 290. Canada Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 291. Canada Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 292. Canada Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 293. Mexico Juvenile Diabetes, by Type USD Million (2019-2024)
  • Table 294. Mexico Juvenile Diabetes, by Application USD Million (2019-2024)
  • Table 295. Mexico Juvenile Diabetes, by Insulin Analog Type USD Million (2019-2024)
  • Table 296. Juvenile Diabetes Sales: by Type(Units)
  • Table 297. Juvenile Diabetes Sales Drugs , by Region Units (2019-2024)
  • Table 298. Juvenile Diabetes Sales Delivery Devices , by Region Units (2019-2024)
  • Table 299. Juvenile Diabetes Sales: by Application(Units)
  • Table 300. Juvenile Diabetes Sales Hospitals , by Region Units (2019-2024)
  • Table 301. Juvenile Diabetes Sales Clinics , by Region Units (2019-2024)
  • Table 302. Juvenile Diabetes Sales Medical Centers , by Region Units (2019-2024)
  • Table 303. Juvenile Diabetes Sales: by Insulin Analog Type(Units)
  • Table 304. Juvenile Diabetes Sales Rapid-Acting Insulin Analogs , by Region Units (2019-2024)
  • Table 305. Juvenile Diabetes Sales Long-Acting Insulin Analogs , by Region Units (2019-2024)
  • Table 306. Juvenile Diabetes Sales Premix Insulin Analogs , by Region Units (2019-2024)
  • Table 307. South America Juvenile Diabetes Sales, by Country Units (2019-2024)
  • Table 308. South America Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 309. South America Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 310. South America Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 311. Brazil Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 312. Brazil Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 313. Brazil Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 314. Argentina Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 315. Argentina Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 316. Argentina Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 317. Rest of South America Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 318. Rest of South America Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 319. Rest of South America Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 320. Asia Pacific Juvenile Diabetes Sales, by Country Units (2019-2024)
  • Table 321. Asia Pacific Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 322. Asia Pacific Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 323. Asia Pacific Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 324. China Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 325. China Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 326. China Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 327. Japan Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 328. Japan Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 329. Japan Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 330. India Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 331. India Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 332. India Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 333. South Korea Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 334. South Korea Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 335. South Korea Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 336. Taiwan Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 337. Taiwan Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 338. Taiwan Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 339. Australia Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 340. Australia Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 341. Australia Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 342. Rest of Asia-Pacific Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 343. Rest of Asia-Pacific Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 344. Rest of Asia-Pacific Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 345. Europe Juvenile Diabetes Sales, by Country Units (2019-2024)
  • Table 346. Europe Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 347. Europe Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 348. Europe Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 349. Germany Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 350. Germany Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 351. Germany Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 352. France Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 353. France Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 354. France Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 355. Italy Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 356. Italy Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 357. Italy Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 358. United Kingdom Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 359. United Kingdom Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 360. United Kingdom Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 361. Netherlands Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 362. Netherlands Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 363. Netherlands Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 364. Rest of Europe Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 365. Rest of Europe Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 366. Rest of Europe Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 367. MEA Juvenile Diabetes Sales, by Country Units (2019-2024)
  • Table 368. MEA Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 369. MEA Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 370. MEA Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 371. Middle East Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 372. Middle East Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 373. Middle East Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 374. Africa Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 375. Africa Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 376. Africa Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 377. North America Juvenile Diabetes Sales, by Country Units (2019-2024)
  • Table 378. North America Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 379. North America Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 380. North America Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 381. United States Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 382. United States Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 383. United States Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 384. Canada Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 385. Canada Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 386. Canada Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 387. Mexico Juvenile Diabetes Sales, by Type Units (2019-2024)
  • Table 388. Mexico Juvenile Diabetes Sales, by Application Units (2019-2024)
  • Table 389. Mexico Juvenile Diabetes Sales, by Insulin Analog Type Units (2019-2024)
  • Table 390. Juvenile Diabetes: by Type(USD/Units)
  • Table 391. Research Programs/Design for This Report
  • Table 392. Key Data Information from Secondary Sources
  • Table 393. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Juvenile Diabetes: by Type USD Million (2013-2018)
  • Figure 5. Global Juvenile Diabetes: by Application USD Million (2013-2018)
  • Figure 6. Global Juvenile Diabetes: by Insulin Analog Type USD Million (2013-2018)
  • Figure 7. South America Juvenile Diabetes Share (%), by Country
  • Figure 8. Asia Pacific Juvenile Diabetes Share (%), by Country
  • Figure 9. Europe Juvenile Diabetes Share (%), by Country
  • Figure 10. MEA Juvenile Diabetes Share (%), by Country
  • Figure 11. North America Juvenile Diabetes Share (%), by Country
  • Figure 12. Global Juvenile Diabetes: by Type Units (2013-2018)
  • Figure 13. Global Juvenile Diabetes: by Application Units (2013-2018)
  • Figure 14. Global Juvenile Diabetes: by Insulin Analog Type Units (2013-2018)
  • Figure 15. South America Juvenile Diabetes Share (%), by Country
  • Figure 16. Asia Pacific Juvenile Diabetes Share (%), by Country
  • Figure 17. Europe Juvenile Diabetes Share (%), by Country
  • Figure 18. MEA Juvenile Diabetes Share (%), by Country
  • Figure 19. North America Juvenile Diabetes Share (%), by Country
  • Figure 20. Global Juvenile Diabetes: by Type USD/Units (2013-2018)
  • Figure 21. Global Juvenile Diabetes share by Players 2018 (%)
  • Figure 22. Global Juvenile Diabetes share by Players (Top 3) 2018(%)
  • Figure 23. Global Juvenile Diabetes share by Players (Top 5) 2018(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Eli Lilly and Company (United States) Revenue: by Geography 2018
  • Figure 27. Bayer Pharmaceuticals (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Bayer Pharmaceuticals (Germany) Revenue: by Geography 2018
  • Figure 29. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi (France) Revenue: by Geography 2018
  • Figure 31. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 32. Novo Nordisk (Denmark) Revenue: by Geography 2018
  • Figure 33. AstraZeneca PLC. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. AstraZeneca PLC. (United Kingdom) Revenue: by Geography 2018
  • Figure 35. XOMA Corp (United States) Revenue, Net Income and Gross profit
  • Figure 36. XOMA Corp (United States) Revenue: by Geography 2018
  • Figure 37. DiaVacs Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. DiaVacs Inc. (United States) Revenue: by Geography 2018
  • Figure 39. B.BraunMelsungen AG (Germany) Revenue, Net Income and Gross profit
  • Figure 40. B.BraunMelsungen AG (Germany) Revenue: by Geography 2018
  • Figure 41. Biodel Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Biodel Inc. (United States) Revenue: by Geography 2018
  • Figure 43. Macrogenics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Macrogenics Inc. (United States) Revenue: by Geography 2018
  • Figure 45. Takeda Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 46. Takeda Pharmaceutical (Japan) Revenue: by Geography 2018
  • Figure 47. Wockhardt Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 48. Wockhardt Ltd. (India) Revenue: by Geography 2018
  • Figure 49. Global Juvenile Diabetes: by Type USD Million (2019-2024)
  • Figure 50. Global Juvenile Diabetes: by Application USD Million (2019-2024)
  • Figure 51. Global Juvenile Diabetes: by Insulin Analog Type USD Million (2019-2024)
  • Figure 52. South America Juvenile Diabetes Share (%), by Country
  • Figure 53. Asia Pacific Juvenile Diabetes Share (%), by Country
  • Figure 54. Europe Juvenile Diabetes Share (%), by Country
  • Figure 55. MEA Juvenile Diabetes Share (%), by Country
  • Figure 56. North America Juvenile Diabetes Share (%), by Country
  • Figure 57. Global Juvenile Diabetes: by Type Units (2019-2024)
  • Figure 58. Global Juvenile Diabetes: by Application Units (2019-2024)
  • Figure 59. Global Juvenile Diabetes: by Insulin Analog Type Units (2019-2024)
  • Figure 60. South America Juvenile Diabetes Share (%), by Country
  • Figure 61. Asia Pacific Juvenile Diabetes Share (%), by Country
  • Figure 62. Europe Juvenile Diabetes Share (%), by Country
  • Figure 63. MEA Juvenile Diabetes Share (%), by Country
  • Figure 64. North America Juvenile Diabetes Share (%), by Country
  • Figure 65. Global Juvenile Diabetes: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Eli Lilly and Company (United States)
  • Bayer Pharmaceuticals (Germany)
  • Sanofi (France)
  • Novo Nordisk (Denmark)
  • AstraZeneca PLC. (United Kingdom)
  • XOMA Corp (United States)
  • DiaVacs Inc. (United States)
  • B.BraunMelsungen AG (Germany)
  • Biodel Inc. (United States)
  • Macrogenics Inc. (United States)
  • Takeda Pharmaceutical (Japan)
  • Wockhardt Ltd. (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation